Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines

by Jan J. Bandolik, Alexandra Hamacher, Christian Schrenk, Robin Weishaupt, Matthias U. Kassack
Published 2019-06-01